These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35098859)

  • 21. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.
    Megna M; Fabbrocini G; Cinelli E; Camela E; Ruggiero A
    J Dermatolog Treat; 2022 Mar; 33(2):1074-1078. PubMed ID: 32705907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
    JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study.
    Megna M; Ruggiero A; Tommasino N; Brescia C; Martora F; Cacciapuoti S; Potestio L
    Clin Cosmet Investig Dermatol; 2024; 17():1037-1042. PubMed ID: 38737943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population.
    Zhuang JY; Li JS; Zhong YQ; Zhang FF; Li XZ; Su H; Zhang ZQ; Wang XH; Chen YF
    Dermatol Ther; 2021 Sep; 34(5):e15054. PubMed ID: 34228392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
    Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
    J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.
    Michelucci A; Manzo Margiotta F; Panduri S; Tonini A; Romanelli M; Morganti R; Janowska A; Dini V
    Dermatol Ther; 2022 Apr; 35(4):e15339. PubMed ID: 35088508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
    Megna M; Potestio L; Fabbrocini G; Ruggiero A
    Psoriasis (Auckl); 2022; 12():205-212. PubMed ID: 35859710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
    Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
    J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.
    Marletta D; Murgia G; Cattaneo A; Carrera C; Marzano A
    J Drugs Dermatol; 2022 Aug; 21(8):864-866. PubMed ID: 35946964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
    Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
    Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
    J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.
    Megna M; Balato A; Caccavale S; Cacciapuoti S; Calabrese G; Di Brizzi EV; Di Costanzo L; Manzo R; Marino V; Puca RV; Romano F; Sarno O; Scotto di Luzio G; Lembo S
    J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731081
    [No Abstract]   [Full Text] [Related]  

  • 35. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
    Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
    J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
    Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
    Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
    Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
    Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
    Seidl U; Pinter A; Wilsmann-Theis D; Poortinga S; Morrison K; Mrowietz U; Gerdes S
    Dermatol Ther; 2022 Jan; 35(1):e15193. PubMed ID: 34741783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.